<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910422-0016</DOCNO><DOCID>910422-0016.</DOCID><HL>   Business Brief -- Cetus Corp.:   Biotechnology Firm's Loss   Shrank in Fiscal 3rd Period</HL><DATE>04/22/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B9</SO><CO>   CTUS</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)EARNINGS (ERN)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>EARNINGS (ERN)</NS><RE>CALIFORNIA (CA)</RE><LP>   Cetus Corp. reported a net loss of $12.9 million, or 39cents a share, for its fiscal third quarter ended March 31,as a 41% increase in revenue narrowed the loss from a yearearlier.   The biotechnology concern, based in Emeryville, Calif.,reported a net loss of $15.9 million, or 56 cents, a yearearlier. Revenue in the latest quarter grew to $13.8 millionfrom $9.8 million a year earlier. The company cited improvingsales of its Proleukin interleukin-2 cancer drug in Europeand of products based on its polymerase chain reaction, orPCR, technology, a process used to amplify and analyze thegenetic code.</LP><TEXT>   For the nine months, Cetus reported a net loss of $52.3million, or $1.64 a share, compared with a net loss of $45million, or $1.62, a year earlier. The latest nine monthsincluded a special charge of $10 million associated withpurchasing affiliated limited partnership interests. Revenuerose 45% to $38.1 million from $26.2 million.</TEXT></DOC>